HUTCHMED China Ltd (HCM) - Total Assets
Based on the latest financial reports, HUTCHMED China Ltd (HCM) holds total assets worth GBX1.75 Billion GBX (≈ $213.30K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can HUTCHMED China Ltd service its debt to assess how comfortably operating cash covers total debt obligations.
HUTCHMED China Ltd - Total Assets Trend (2005–2025)
This chart illustrates how HUTCHMED China Ltd's total assets have evolved over time, based on quarterly financial data. See HUTCHMED China Ltd shareholders equity for net asset value and shareholders' equity analysis.
HUTCHMED China Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
HUTCHMED China Ltd's total assets of GBX1.75 Billion consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 4.1% |
| Accounts Receivable | GBX147.63 Million | 8.4% |
| Inventory | GBX41.07 Million | 2.4% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX8.93 Million | 0.5% |
| Goodwill | GBX3.11 Million | 0.2% |
Asset Composition Trend (2005–2025)
This chart illustrates how HUTCHMED China Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HCM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HUTCHMED China Ltd's current assets represent 89.4% of total assets in 2025, an increase from 47.7% in 2005.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 8.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 19.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
HUTCHMED China Ltd Competitors by Total Assets
Key competitors of HUTCHMED China Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥11.40 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
HUTCHMED China Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.96 | 2.83 | 3.35 |
| Quick Ratio | 4.83 | 2.70 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX1.25 Billion | GBX689.99 Million | GBX372.34 Million |
HUTCHMED China Ltd - Advanced Valuation Insights
This section examines the relationship between HUTCHMED China Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 37.4% |
| Total Assets | GBX1.75 Billion |
| Market Capitalization | $17.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values HUTCHMED China Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: HUTCHMED China Ltd's assets grew by 37.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HUTCHMED China Ltd (2005–2025)
The table below shows the annual total assets of HUTCHMED China Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX1.75 Billion ≈ $213.01K |
+37.40% |
| 2024-12-31 | GBX1.27 Billion ≈ $155.03K |
-0.44% |
| 2023-12-31 | GBX1.28 Billion ≈ $155.71K |
+24.32% |
| 2022-12-31 | GBX1.03 Billion ≈ $125.25K |
-25.00% |
| 2021-12-31 | GBX1.37 Billion ≈ $167.01K |
+89.56% |
| 2020-12-31 | GBX724.12 Million ≈ $88.10K |
+55.68% |
| 2019-12-31 | GBX465.12 Million ≈ $56.59K |
-12.59% |
| 2018-12-31 | GBX532.12 Million ≈ $64.74K |
-11.01% |
| 2017-12-31 | GBX597.93 Million ≈ $72.75K |
+74.61% |
| 2016-12-31 | GBX342.44 Million ≈ $41.66K |
+49.05% |
| 2015-12-31 | GBX229.75 Million ≈ $27.95K |
+4.94% |
| 2014-12-31 | GBX218.94 Million ≈ $26.64K |
+17.92% |
| 2013-12-31 | GBX185.67 Million ≈ $22.59K |
-11.36% |
| 2012-12-31 | GBX209.47 Million ≈ $25.49K |
+7.54% |
| 2011-12-31 | GBX194.77 Million ≈ $23.70K |
+21.79% |
| 2010-12-31 | GBX159.93 Million ≈ $19.46K |
+25.18% |
| 2009-12-31 | GBX127.75 Million ≈ $15.54K |
+8.31% |
| 2008-12-31 | GBX117.96 Million ≈ $14.35K |
-7.53% |
| 2007-12-31 | GBX127.56 Million ≈ $15.52K |
-4.12% |
| 2006-12-31 | GBX133.04 Million ≈ $16.19K |
+111.58% |
| 2005-12-31 | GBX62.88 Million ≈ $7.65K |
-- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more